BioCardia is advancing two regulatory programs, targeting a CardiAMP HF Shonin pre-market submission in 2026 and a Helix follow-on De Novo pre-submission in the current quarter. The timelines matter because PMDA support could lead to market clearance in 2027, while independent FDA clearance could broaden partnering opportunities.
Key Highlights
- BioCardia is working toward a CardiAMP HF Shonin pre-market submission to Japan’s PMDA in 2026.
- PMDA support and a successful review could lead to CardiAMP HF market clearance in 2027.
- BioCardia is preparing a Shonin pre-market application for Japan’s Pharmaceutical and Medical Device Agency, targeting submission during 2026.
- The CardiAMP HF II confirmatory study is enrolling in the United States and may support a U.S. Premarket Approval application, according to FDA feedback.
BioCardia, Inc. (NASDAQ: BCDA) is a biotechnology company advancing regulatory milestones for its cardiovascular therapies and delivery technology. The company is targeting a CardiAMP HF submission in Japan during 2026 and plans to move its Helix program into another FDA review step during the current quarter.
CardiAMP HF and Helix Move Toward Review
BioCardia is preparing a Shonin pre-market application for Japan’s Pharmaceutical and Medical Device Agency, after supplying detailed answers to consultation questions. The CardiAMP HF II confirmatory study is enrolling in the United States. The FDA’s Center for Biologics Evaluation and Research has indicated that the study may support a Premarket Approval application.
Potential Clearance and Partnering Path
The statement concerns the Japanese regulatory pathway and its potential outcome. The company also identified the CardiAMP HF II study as a possible basis for a U.S. Premarket Approval application.
FAQs
Q: What is BioCardia planning for CardiAMP HF in Japan?
A: BioCardia is working toward a Shonin pre-market regulatory submission to Japan’s PMDA during 2026. The program involves CardiAMP autologous cell therapy for ischemic heart failure.
Q: What is the Helix FDA regulatory plan?
A: BioCardia plans to move its Helix program into another FDA review step during the current quarter.
Q: When could CardiAMP HF receive Japanese market clearance?
A: PMDA support for the submission and a successful review could result in CardiAMP HF market clearance during 2027. The outcome remains tied to the Japanese regulatory process.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.